We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The Efficacy and Safety of Dexibuprofen Syrup

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00812422
Recruitment Status : Completed
First Posted : December 22, 2008
Last Update Posted : January 18, 2010
Information provided by:

December 19, 2008
December 22, 2008
January 18, 2010
February 2008
May 2009   (Final data collection date for primary outcome measure)
measure reduction in fever [ Time Frame: measure temperature every hour for 3 hours then once again 3 days later ]
Same as current
Complete list of historical versions of study NCT00812422 on ClinicalTrials.gov Archive Site
determine safety of dexibuprofen by unwanted reaction, clinical laboratory test and physical examination. [ Time Frame: every hour for 3 hours (unwanted reaction). 3 days later (clinical laboratory test and physical examination). ]
Same as current
Not Provided
Not Provided
The Efficacy and Safety of Dexibuprofen Syrup
Multi-center, Randomized, Double Blinded (Double-dummy), Active-Controlled Parallel-group Comparative, Phase 3 Clinical Trial to Assess the Efficacy and Safety of Dexibuprofen Syrup Compared to Ibuprofen Syrup in Patients With Fever of Common Cold (Acute Upper Respiratory Infection)
The purpose of this study is to compare the safety and efficacy of dexibuprofen syrup and ibuprofen syrup in patients with fever due to common cold.
Not Provided
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
  • Fever
  • Respiratory Tract Infection
  • Drug: Dexibuprofen
    one dose of Dexibuprofen 2.5 or 5 mg/kg
  • Drug: Dexibuprofen
    one dose of Dexibuprofen 3.5 or 7 mg/kg
  • Drug: Ibuprofen
    one dose of Ibuprofen 5 or 10 mg/kg
  • Experimental: Dexibuprofen 1
    Dexibuprofen 2.5 or 5 mg/kg
    Intervention: Drug: Dexibuprofen
  • Experimental: Dexibuprofen 2
    Dexibuprofen 3.5 or 7 mg/kg
    Intervention: Drug: Dexibuprofen
  • Active Comparator: Ibuprofen
    Ibuprofen 5 or 10 mg/kg
    Intervention: Drug: Ibuprofen
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
May 2009
May 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Common cold with fever
  • Age 6 months to 14 years

Exclusion Criteria:

  • Gastric ulcer
  • Bleeding tendency
  • Liver disease
  • Kidney disease
  • Hypertension
  • Hypersensitivity to the drug
Sexes Eligible for Study: All
6 Months to 14 Years   (Child)
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
Not Provided
Not Provided
Chang-Keun Kim, Inje University Sanggye Paik Hospital
Inje University
Not Provided
Study Director: Young Yull Koh Seoul National University Hospital
Principal Investigator: Chang-Keun Kim Inje University
Inje University
January 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP